DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Email Jefferies - 1 Michael Yee - 1 Jefferies - 1
Top related locs:
Top related orgs:

Search resuls for: "Michael Yee"


15 mentions found


☆ Jefferies' Michael Yee expects big opportunities for A.I. in the biotech sector
  + stars: | 2023-06-02 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJefferies' Michael Yee expects big opportunities for A.I. in the biotech sectorMichael Yee, Jefferies equity analyst, joins 'Power Lunch' to discuss AI's potential impact on the biotech sector.
Persons: Email Jefferies, Michael Yee, Jefferies
☆ Jefferies' Michael Yee expects Amgen's Horizon Therapeutics deal will go through despite FTC block
  + stars: | 2023-05-16 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJefferies' Michael Yee expects Amgen's Horizon Therapeutics deal will go through despite FTC blockMichael Yee, Jefferies managing director, joins 'Power Lunch' to discuss the FTC's move to block Amgen's $27.8 billion deal for Horizon Therapeutics.
☆ Moderna says it expects up to $15 billion in sales of Covid, RSV, flu vaccines in 2027
  + stars: | 2023-04-11 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +1 min
Moderna on Tuesday said it expects to see between $8 billion and $15 billion in sales from its Covid, RSV, flu and other respiratory vaccines in 2027. The biotech company said it sees a corresponding operating profit in the range of $4 billion to $9 billion. Those respiratory product estimates are supported by additional research investments of $6 billion to $8 billion "over the next few years," Moderna added. Moderna said earlier this year it expects $5 billion in mRNA Covid vaccine sales in 2023, a steep drop from the $18 billion the shot raked in last year. The Cambridge, Massachusetts-based company's Covid vaccine remains its only commercially available product.
☆ Eli Lilly Alzheimer's drug setback extends rival Biogen's lead - analysts
  + stars: | 2023-01-20 | by ( ) www.reuters.com   time to read: +2 min
Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said. "This is a modest positive for Biogen" because it delays donanemab's launch, Jefferies analyst Michael Yee said, adding that Eli Lilly could file for traditional approval by mid-2023. The setback for Lilly comes just weeks after the FDA granted Biogen Inc (BIIB.O) and Japanese drugmaker Eisai Co Ltd's (4523.T) accelerated approval for their Alzheimer's drug Leqembi. read moreAnalysts are waiting for the traditional approval of Biogen's drug and for wider health insurance coverage before they expect sales of the drug to pick up. "But if there is anything wrong with the (Eli Lilly) data set, it is easier to reject an unapproved drug than remove an approved drug from market," said Skorney.
☆ Moderna's mRNA RSV vaccine propels stock gains
  + stars: | 2023-01-18 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna's mRNA RSV vaccine propels stock gainsMichael Yee, managing director at Jefferies, joins 'The Exchange' to discuss what's driving Moderna's stock activity, the unique mRNA technology behind the company's RSV vaccine and portfolio opportunities in the biotech business.
☆ Jefferies' Michael Yee on Biogen as FDA could be on the verge of approving Alzheimer's drug
  + stars: | 2023-01-06 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJefferies' Michael Yee on Biogen as FDA could be on the verge of approving Alzheimer's drugMichael Yee, Jefferies managing director, joins 'The Exchange' to discuss biotech and the FDA's looming decision on Biogen's second Alzheimer's drug.
☆ Jefferies' Michael Yee still likes Amgen in the biotech sector
  + stars: | 2022-12-27 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailJefferies' Michael Yee still likes Amgen in the biotech sectorMichael Yee, Jefferies biotech analyst, joins 'Closing Bell' to discuss biotech, which is on pace for its worst year since 2016.
☆ Jefferies upgrades Moderna, citing optimism around promising experimental cancer vaccine
  + stars: | 2022-12-19 | by ( Sarah Min | ) www.cnbc.com   time to read: +1 min
Moderna has a game-changing drug pipeline for 2023, according to Jefferies. Analyst Michael Yee upgraded Moderna to buy from hold, saying a promising new cancer vaccine from the pharmaceutical company has renewed interest in the stock. The Covid vaccine story is old and numbers came way down already and most investors don't care much on this anymore. New story is now PCV cancer vaccine opportunity, Phase III RSV data coming up, doublet and triplet virus vaccines in 2023," Yee wrote in a Monday note. "We see stock rebounding back up in 2023, a return of pipeline opportunities and a 'story stock' as generalist and HC interest revisits the stock," Yee added.
☆ Moderna shifts focus to developing cancer vaccinations
  + stars: | 2022-12-19 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna shifts focus to developing cancer vaccinationsMichael Yee of Jefferies joins 'Closing Bell' to discuss Moderna's shift away from Covid-focused pharmaceuticals toward PCV cancer vaccination, the market size for personalized cancer vaccines and the Moderna-Merck partnership.
☆ Watch CNBC's full interview with Jefferies' Michael Yee
  + stars: | 2022-11-22 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Jefferies' Michael YeeMichael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and whether it's too late to 'nibble' on stocks in the sector.
☆ We still think there's more room for biotech to go higher, says Jefferies' Yee
  + stars: | 2022-11-22 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWe still think there's more room for biotech to go higher, says Jefferies' YeeMichael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late to 'nibble' on stocks in the sector.
☆ Analysis: Falling demand for COVID boosters puts price hikes on the table
  + stars: | 2022-10-20 | by ( Michael Erman | ) www.reuters.com   time to read: +5 min
Last year, many on Wall Street were estimating the number of COVID-19 shots would be in line with the annual flu vaccine, which is the vaccine market leader with more than 160 million shots per year in the United States and 600 million shots globally. A recent poll by Kaiser Family Foundation found that two-thirds of American adults do not plan on getting a COVID vaccine soon. He added that instances of COVID infections in those who have been vaccinated has left many to question the effectiveness of the vaccine. The companies could make up for some of the weaker demand with price increases. That would mean annual revenue of $3 billion to $5 billion over the long-term for a company like Moderna, he added.
☆ Moderna to develop a personalized cancer vaccine with Merck
  + stars: | 2022-10-12 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailModerna to develop a personalized cancer vaccine with MerckMichael Yee, Jefferies managing director, joins 'Closing Bell' to share details on the Moderna and Merck announcement about a personalized cancer treatment for people with melanoma and what it means for Q3 earnings.
☆ Alzheimer's drug study yields positive results, say makers Eisai and Biogen
  + stars: | 2022-09-27 | by ( Deena Beasley Julie Steenhuysen Rocky Swift | Deena Beasley | Julie Steenhuysen | ) www.reuters.com   time to read: +6 min
Globally, the figure could reach 139 million by 2050 without an effective treatment, Alzheimer's Disease International said. Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry. read morePatient advocacy groups hailed the news of positive lecanemab trial results. Micro hemorrhages in the brain occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group. Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.
☆ The biggest wave of Covid injections are behind us, says Jefferies' Michael Yee
  + stars: | 2022-09-19 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe biggest wave of Covid injections are behind us, says Jefferies' Michael YeeJefferies analyst Michael Yee joins 'Closing Bell' to discuss biotech and pharmaceutical stocks and how President Biden's comments yesterday that the pandemic is over are impacting those stocks.
<< prev 1 next >>
Total: 15